Key result
High C-reactive protein-to-albumin ratio is linked to ~45% higher MACCE risk, especially with diabetes.
Why the study?
The role of the C-reactive protein-to-albumin ratio in predicting outcomes among acute decompensated heart failure patients, particularly stratified by glycemic status, was poorly defined.
Does a high C-reactive protein-to-albumin ratio predict major adverse cardiac and cerebrovascular events in patients with acute decompensated heart failure across different glucose metabolism statuses?
Cohort (n=1,494)
No
Does a high C-reactive protein-to-albumin ratio predict major adverse cardiac and cerebrovascular events in patients with acute decompensated heart failure across different glucose metabolism statuses?
The C-reactive protein-to-albumin ratio is an independent prognostic biomarker for major adverse cardiovascular events in patients with acute decompensated heart failure, particularly those with concomitant diabetes.
The C-reactive protein-to-albumin ratio (CAR) is an emerging biomarker linked to cardiovascular disease. However, its role in predicting outcomes among acute decompensated heart failure (ADHF) patients, particularly when stratified by glycemic status, remains poorly defined. This retrospective study included 1,494 consecutive ADHF patients admitted between 2018 and 2023, with the primary endpoint being major adverse cardiac and cerebrovascular events (MACCEs). Patients were stratified into low- and high-CAR groups using an optimal cutoff of 0.29, derived from maximally selected rank statistics. To assess the relationship between CAR and MACCEs in different glucose metabolism states, multivariable Cox proportional hazards models, restricted cubic splines (RCS), and Kaplan-Meier survival curves were used. During a median follow-up of 528 days, 565 patients (37.8%) experienced MACCEs. After adjusting for potential confounders, higher CAR levels were significantly associated with an increased risk of MACCEs (Model 3: hazard ratio [HR]: 1.45, 95% confidence interval [CI]: 1.19-1.77, p < 0.001). When stratified by glycemic status, CAR as a robust predictor in diabetic patients (Model 3 HR: 1.91, 95% CI: 1.41-2.58, p < 0.001), whereas no significant associations were observed in prediabetic or normoglycemic individuals (all p > 0.05). In conclusion, CAR demonstrates independent prognostic value in ADHF patients with concomitant diabetes, highlighting its potential as a stratification tool for personalized risk assessment and therapeutic optimization in this high-risk population.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted a cohort in Acute decompensated heart failure (n=1,494). High C-reactive protein-to-albumin ratio (CAR ≥ 0.29) vs. Low C-reactive protein-to-albumin ratio (CAR < 0.29) was evaluated on Major adverse cardiac and cerebrovascular events (MACCEs) (HR 1.45, 95% CI 1.19-1.77, p=<0.001). A high C-reactive protein-to-albumin ratio was significantly associated with an increased risk of major adverse cardiac and cerebrovascular events (HR 1.45), with the strongest predictive value in patients with concomitant diabetes (HR 1.91).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: